Oncomine Myeloproliferative Neoplasm (MPN) Panel – Accurate NGS Testing for MPN Mutations

The Oncomine Myeloproliferative Neoplasm (MPN) Panel from Lab Tests Dubai is a state-of-the-art next-generation sequencing (NGS) assay designed to deliver comprehensive genetic profiling for patients with suspected or confirmed myeloproliferative neoplasms (MPNs) including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

Unlike traditional PCR tests that screen only for known mutations (e.g., JAK2 V617F), this advanced panel analyzes over 30 clinically relevant genes associated with MPNs, enabling:

• ✅ Definitive diagnosis in ambiguous cases
• ✅ Accurate subtyping of MPN disorders
• ✅ Risk stratification based on mutational burden
• ✅ Guidance for targeted therapies (e.g., ruxolitinib)
• ✅ Monitoring disease progression and treatment response

Key genes tested include:

• JAK2, CALR, MPL – Driver mutations in >90% of MPN cases
• ASXL1, TET2, SRSF2, SF3B1, U2AF1, EZH2, DNMT3A, IDH1/IDH2 – Prognostic markers linked to disease progression and leukemic transformation

With results in just 10–14 days, Lab Tests Dubai empowers hematologists to move beyond symptom-based diagnosisand embrace precision medicine so patients receive personalized care based on their unique genetic profile.

Available through partner hematology centers, this test ensures high sensitivity, reliability, and clinical actionability making it an indispensable tool in modern MPN management.

Why You Need This Test

If you’ve been diagnosed with high red blood cells, platelets, or unexplained splenomegaly, this test could reveal the underlying genetic cause so your doctor can confirm MPN type, assess risk, and choose the right treatment.

You need the Oncomine MPN Panel if:

• You have elevated hemoglobin or hematocrit (suspected PV)
• Your platelet count is persistently high (suspected ET)
• You have splenomegaly, fatigue, or bone marrow fibrosis (possible PMF)
• You’re being evaluated for ruxolitinib or other JAK inhibitors
• You want molecular confirmation beyond JAK2 V617F testing
• You’re at risk of disease progression or AML transformation

This test helps:

• Confirm MPN diagnosis when standard tests are inconclusive
• Distinguish between PV, ET, and PMF based on mutation patterns
• Identify high-risk mutations (e.g., ASXL1, SRSF2) linked to poor outcomes
• Guide use of targeted therapies
• Monitor clonal evolution over time

Precision earlier intervention, better outcomes.

Who Should Consider This Test?

The Oncomine MPN Panel is recommended for:

• Patients with Unexplained Blood Count Abnormalities

Such as elevated RBCs, WBCs, or platelets.

• Those with Suspected or Confirmed MPNs

To subtype and risk-stratify disease.

• Individuals Being Evaluated for JAK Inhibitor Therapy

e.g., ruxolitinib, fedratinib.

• Patients Showing Signs of Progression

Like worsening cytopenias, splenomegaly, or blast increase.

• Hematologists & Oncologists

Seeking comprehensive molecular workup for MPN patients.

This test aligns with WHO and NCCN guidelines for MPN diagnosis and is increasingly considered standard of care in advanced hematological practice.

What Does the Test Reveal?

Using Ion Torrent™ NGS technology, the panel detects:

• 🔬 Single Nucleotide Variants (SNVs) – e.g., JAK2 V617F, IDH2 R140Q
• 🔬 Insertions/Deletions (Indels) – including CALR exon 9 insertions
• 🔬 Copy Number Variations (CNVs) – gene amplifications/deletions
• 🔬 Spliceosome Mutations – SF3B1, SRSF2, U2AF1 (linked to progression)

Key Clinical Implications

These findings enable refined classification, prognostication, and treatment planning.

What Happens If You Skip Molecular Profiling?

Without comprehensive NGS testing, MPN patients may:

• Receive inaccurate diagnosis due to overlapping symptoms
• Be misclassified into wrong risk category
• Miss targeted therapy eligibility (e.g., JAK inhibitors)
• Experience delayed intervention during progression
• Undergo unnecessary procedures without genetic clarity

The good news? MPNs are manageable with precision care:

• Ruxolitinib improves symptoms in MF and PV
• Early identification of high-risk mutations allows closer monitoring
• Clinical trials target IDH, BET, and MDM2 pathways

Early testing slowed progression and improved quality of life.

How to Prepare for the Test

To ensure accurate results:

• Peripheral Blood (EDTA tube) – most common

• Bone Marrow Aspirate – preferred for early fibrosis or progression

• DNA Extracts – if previously isolated

• No fasting required

• Inform your doctor of:

• Current medications (e.g., hydroxyurea, aspirin)

• Prior treatments or transfusions

• Family history of blood disorders

Your hematologist will coordinate sample submission to our partner lab.

Test Overview: Oncomine MPN NGS Panel

Report Includes

• Detected mutations with variant allele frequency (VAF)
• WHO/NCCN guideline alignment
• Prognostic significance (favorable vs. adverse)
• Therapeutic implications (FDA-approved or investigational drugs)
• Recommendations for follow-up testing

Note: Often used alongside bone marrow biopsy, cytogenetics, and serum EPO levels.

Benefits of the Oncomine MPN Panel

• Detects All Major MPN Drivers

JAK2, CALR, MPL – in one test.

• Identifies High-Risk Mutations

Predicts progression to myelofibrosis or AML.

• Guides Targeted Therapy

Supports use of JAK inhibitors and clinical trials.

• Reduces Diagnostic Delays

Replaces multiple single-gene tests.

• Monitors Clonal Evolution

Track changes over time for early intervention.

If you or a loved one is facing unexplained high blood counts or a suspected MPN, the Oncomine MPN Panel gives you the answers you need in 10–14 days.